Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ATI-3009
- Development stage
- Preclinical
- Lead developer
- Antidote Therapeutics
- Modality
- Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Administration
- Intravenous (preclinical Studies)
01
Overview
ATI-3009 is a recombinant bacterial nicotine-degrading enzyme (NicA2 variant) developed to treat nicotine addiction and aid in smoking cessation. It works by rapidly metabolizing nicotine in the bloodstream before it can reach the brain, thereby reducing or eliminating its addictive and reinforcing effects. The engineered variant (ATI-3009) demonstrates increased catalytic activity, longer half-life, and reduced immunogenicity compared to wild-type enzymes. Preclinical studies have shown that ATI-3009 can significantly lower brain nicotine levels without observed toxicities in animal models. The drug is being developed as a novel approach for smoking withdrawal and relapse prevention by Antidote Therapeutics and collaborators[1][6].
- Other names
- Nicotine degrading enzyme
Beyond the preview
Go deeper on ATI-3009.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ATI-3009.